FDA grants accelerated approval to AstraZeneca's Etcamah for certain breast cancers, boosting stock sentiment.
AstraZeneca's drug Etcamah (camizestrant) received accelerated FDA approval for use with CDK4/6 inhibitors in hormone receptor positive, HER2 negative metastatic breast cancer patients with ESR1 mutations. This approval follows earlier European clear...
